Current diagnostic methods for prostate cancer (PCa) include serum prostate-specific antigen (PSA), transrectal ultrasound (TRUS), digital rectal examination (DRE), magnetic resonance imaging (MRI), and tissue biopsy. This evidence concerns the gene KLK3 and prostate cancer.